NasdaqGS:TSHABiotechs
Does Rett Trial Data and Share Offering Reshape the Bull Case for Taysha Gene Therapies (TSHA)?
Earlier this week, Taysha Gene Therapies announced an underwritten public offering of 32.5 million common shares at US$6.00 each after releasing updated Part A REVEAL study data for TSHA-102 in Rett syndrome.
The new REVEAL data positions TSHA-102 as a potential first disease-modifying gene therapy for Rett syndrome, which could be important for both patients and Taysha’s gene therapy platform.
With fresh REVEAL Part A data supporting TSHA-102’s disease-modifying potential, we’ll examine how...